Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting.

Presentations include new Rhapsido (remibrutinib) data highlighting changes in daily itch and hives severity scores at week 1 in patients with Chronic Spontaneous Urticaria (CSU), an indirect comparison on Cosentyx (secukinumab) safety and flare prevention for patients with Hidradenitis Suppurativa (HS) vs. bimekizumab, as well as four- and five-year efficacy data from pivotal trials in HS and psoriasis, respectively.

“Novartis data at this year’s AAD build on the robust body of evidence for the use of Rhapsido and Cosentyx in their approved dermatological indications. These presentations also demonstrate the strength of our immunology portfolio and our ongoing efforts to help patients manage chronic diseases that significantly impact their lives and overall well-being,” said Angelika Jahreis, Global Head, Immunology Development, Novartis.